<DOC>
	<DOCNO>NCT00452582</DOCNO>
	<brief_summary>Stroke third lead cause death United States lead cause serious long-term disability . Approximately 50 % 750,000 people affect stroke year residual physical impairment . Treatment option recovery limited time . Sildenafil ( Viagra ) demonstrate capability significantly improve recovery several animal experiment stroke . This study aim establish safety treatment sildenafil people stroke ultimate aim test usefulness improve recovery .</brief_summary>
	<brief_title>Sildenafil ( Viagra ) Treatment Subacute Ischemic Stroke</brief_title>
	<detailed_description>Stroke third lead cause death lead cause serious long-term disability United States . Approximately 15-30 % stroke survivor permanently disable . Twenty eight percent stroke patient age 65 result loss work income . While many restorative therapy tout promising treatment ischemic stroke , date none approve purpose . Sildenafil ( Viagra® ) , phosphodiesterase type 5 inhibitor , show reduce mortality improve functional outcome young age rat administer 24 hour 7 day stroke onset . Such result encourage warrant investigation human stroke . The specific aim study assess safety treat ischemic stroke patient sildenafil ( Viagra® ) evaluate outcome day 90 . This phase I dose-escalation study cohort size 12 patient ( depend occurrence serious adverse event ) . A total enrollment 120 patient plan . Patients 4 7 day stroke onset receive 25 , 50 , 75 , 100 , 125 , 150 , 175 , 200 mg daily sildenafil period 14 day . Of 120 patient , 24 randomly select receive standard treatment receive sildenafil . All patient physician aware treatment assignment . Evaluation potential toxicity monitor throughout course treatment formal visit day 16 initiation treatment . Plasma monitor vascular endothelial growth factor ( VEGF ) make prior treatment , day 7 , 16 , 30 , 60 , 90 . Measurements NIHSS score , Rankin score , Barthel index make day 30 , 60 , 90 . Patients also assess color vision change sexual function day 16 day 90 visit . There every day phone call patient treatment . The primary outcome measure death , recurrent stroke , myocardial infarction treatment . Exploratory analysis include functional outcome measure neurological scale , change VEGF level relation clinical outcome . The long-term objective identify safe easily administer treatment improve functional outcome patient ischemic stroke .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Patients ischemic stroke 4 7 day symptom onset . Patients age 1880 year old . NIHSS score 521 prior treatment ( within cohort , 4 patient NIHSS &lt; 9 few 4 patient NIHSS &gt; 11 ) . Signed IRBapproved informed consent patient authorize representative . General : Participation another study investigational drug device . Women know pregnant , lactating , childbearing potential positive urine betaHCG . Patients receive oral medication . Patients use sildenafil phosphodiesterase inhibitor within previous 7 day stroke . Safety Related : Unstable angina . Myocardial infarction within 3 month . Current use nitrate agent . Current use alphachannel antagonist . Current use medication inhibit cytochrome p450 3A4 system . These medication include : amiodarone , aprepitant , bosentan , cimetidine , cisapride , clarithromycin , delavirdine , diltiazem , efavirenz , erythromycin , fluconazole , fluvoxamine , grapefruit juice , imatinib , itraconazole , ketoconazole , loratadine , mibefradil , mifepristone ( RU486 ) , niacin , nefazodone , quinidine , quinine , ritonavir , saquinavir , tacrolimus , verapamil , voriconazole . St. John 's Wort phenytoin ( inducer cytochrome P450 3A4 ) Baseline systolic blood pressure le 100 mmHg . Penile deformity . Creatinine &gt; 1.5 . Abnormal liver function study . Patients previous history sudden monocular vision loss Potentially Interfering Outcomes Assessment : Prior history dementia . Patients without fixed address deem unlikely present followup investigator . Patients whose life expectancy le 90 day . Prestroke modify Rankin score &gt; 2 . Glucose great equal 400 mg/dL presentation . Other serious illness ( e.g. , severe hepatic , cardiac , renal failure ; acute myocardial infarction ; complex disease may confound treatment assessment ) . Previous stroke TIA within 30 day . Allergy hypersensitivity sildenafil phosphodiesterase inhibitor . History sudden monocular visual disturbance . History sudden unilateral hearing problem . Imaging Related : Evidence primary intraparenchymal hemorrhage initial neuroimaging study . Neuroimaging evidence nonvascular cause neurological symptom .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>ischemic stroke</keyword>
	<keyword>recovery</keyword>
	<keyword>sildenafil</keyword>
</DOC>